SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…
- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society…
OLDWICK, N.J.--(BUSINESS WIRE)--#insurance--Reinsurance pricing at the midyear 2025 renewals was the most favorable pricing for cedents in recent years, indicating…
- Presentations highlight clinically meaningful reductions in BMI in patients with acquired hypothalamic obesity – - Full data from Phase…
Resilient Pricing Despite Challenging and Uncertain End Market Conditions; Additional Structural Cost Reductions RealizedTUCKER, Ga.--(BUSINESS WIRE)--GMS Inc. (NYSE: GMS), a…
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall…